Therapy with pembrolizumab in treatment‐naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer
International Journal of Cancer · 2023
DOI: 10.1002/ijc.34420 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Rikke Løvendahl Eefsen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Rectal Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Therapy with immune checkpoint inhibitors (ICI) is effective in patients with metastatic mismatch‐repair deficient (dMMR) colorectal cancer (CRC); however, data on treatment with neoadjuvant ICI in patients with locally advanced CRC are limited. From March 2019 to June 2020, five Danish oncological centers treated 10 patients with a treatment‐naïve dMMR CRC with preoperative pembrolizumab, 9 with a nonmetastatic, unresectable colon cancer and 1 with a locally advanced rectum cancer. All 10 patients were evaluated regularly at a multidisciplinary team (MDT) meeting, and they all had a radical resection after a median of 8 cycles (range 2‐13) of pembrolizumab. A microscopic evaluation of the resected tumors revealed no remaining tumor cells in five patients, while five still had tumor cells present. The patients were given no additional therapy. No recurrences were reported after a median follow‐up of 26 months (range 23‐38.5 months). Biopsies from Danish patients with CRC are routinely screened for dMMR proteins. In 2017, data from the Danish Colorectal Cancer Group showed that 19% (565/3000) of the patients with colon cancer and 1.5% (19/1279) of those with rectum cancer had an dMMR tumor. Among the patients with MMR determination, 26% (99/384) patients had a T4 dMMR colon cancer; thus, the 10 patients treated with neoadjuvant pembrolizumab comprised about 9% of the patients with a T4 dMMR colon cancer (9/99) and 5% of patients with dMMR rectal cancer (1/19). Therapy with pembrolizumab was feasible and effective. Larger prospective trials are needed to confirm our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark.
- Department of Pathology, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Oncology, Zealand University Hospital, Roskilde, Denmark.
- Department of Surgery, Copenhagen University Hospital-Herlev and Gentofte, Herlev, Denmark.
- Department of Oncology, Odense University Hospital, Odense, Denmark.
ORCID-Profile: Rikke Løvendahl Eefsen, Benny V Jensen
Zitieren
APA
Eefsen, R. L., Larsen, J. S., Klarskov, L. L., Altaf, R., Høgdall, E., Ingeholm, P., Lykke, J., Nielsen, D. L., Pfeiffer, P., Poulsen, L. Ø., Qvortrup, C., Schou, J. V., Mau-Sørensen, M., Østerlind, K., & Jensen, B. V. (2023). Therapy with pembrolizumab in treatment‐naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.34420
Vancouver
Eefsen RL, Larsen JS, Klarskov LL, Altaf R, Høgdall E, Ingeholm P, et al. Therapy with pembrolizumab in treatment‐naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer. International Journal of Cancer. 2023. doi:10.1002/ijc.34420
BibTeX
@article{Eefsen2023,
author = {Eefsen, Rikke Løvendahl and Larsen, Jim S and Klarskov, Louise L and Altaf, Rahim and Høgdall, Estrid and Ingeholm, Peter and Lykke, Jakob and Nielsen, Dorte L and Pfeiffer, Per and Poulsen, Laurids Ø and Qvortrup, Camilla and Schou, Jakob V and Mau-Sørensen, Morten and Østerlind, Kell and Jensen, Benny V},
title = {Therapy with pembrolizumab in treatment‐naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer},
journal = {International Journal of Cancer},
year = {2023},
doi = {10.1002/ijc.34420}
}
EUVIMED